Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)1,198.00
  • Today's Change8.00 / 0.67%
  • Shares traded879.81k
  • 1 Year change-38.94%
  • Beta1.3393
Data delayed at least 20 minutes, as of Oct 20 2017 17:11 BST.
More ▼

Key statistics

On Friday, Hikma Pharmaceuticals PLC (HIK:LSE) closed at 1,198.00, 8.81% above its 52-week low of 1,101.00, set on Aug 17, 2017.
52-week range
Today
1,101.00Aug 17 20172,346.00Mar 16 2017
Markit short selling activity
Low
Med
High
Open1,195.00
High1,198.00
Low1,174.00
Bid1,110.00
Offer1,220.00
Previous close1,190.00
Average volume730.85k
Shares outstanding240.65m
Free float131.76m
P/E (TTM)22.83
Market cap2.88bn GBP
EPS (TTM)0.5236
GBP
Annual div (ADY)26.50
GBX
Annual div yield (ADY)2.24%
Div ex-dateAug 24 2017
Div pay-dateSep 22 2017
Data delayed at least 20 minutes, as of Oct 20 2017 17:11 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Sell at 1,212.00 on 18 Aug 2017Read the full article

Board of Directors

1/12

Said Darwazah, Chairman and Chief Executive

2/12

Mazen Darwazah, Executive Vice Chairman, Chief Executive of MENA and Emerging Markets

3/12

Ali Al-Husry, Non-Executive Director

4/12

Dr. Jochen Gann, Non-Executive Director

5/12

Robert Pickering, Chair of the Nomination Committee

6/12

Dr. Pamela Kirby, Chair Remuneration Committee

7/12

Michael Ashton, Independent Non-Executive Director

8/12

Dr. Ronald Goode, Chair Compliance, Responsibility and Ethics Committee

9/12

Patrick Butler, Chair Audit Committee

10/12

John Castellani, Independent Non-Executive Director

11/12

Nina Henderson, Independent Non-Executive Director

12/12

Peter Speirs, Company Secretary

Investor Relations Contact

Hikma Pharmaceuticals PLC

1 New Burlington Place,

London

W1S 2H

Tel: +44 (0) 20 7399 2760

Fax: +44 (0) 20 7399 2761

Email: investors@hikma.uk.co

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.